This website has been developed and fully funded by Janssen-Cilag Ltd. and is intended for UK patients prescribed Tremfya®▼ (guselkumab) only.

Information on COVID-19 for patients using Tremfya® (guselkumab)
Using your medication
pre-filled pen

What is Tremfya®?1

The medication you have been prescribed for your psoriasis is a biologic treatment and comes as an injectable pre-filled pen for administration by injection under the skin (subcutaneous injection).1

Each pre-filled pen contains 100 mg of guselkumab in a 1 mL solution.1

A biologic treatment is a medicine made of protein that is grown from living cells in a laboratory, which targets specific parts of the immune system.2 In particular, your medication works by blocking the activity of a protein called interleukin 23 (IL-23), which is present at increased levels in people with psoriasis.1 It may improve the condition of the skin and appearance of nails and reduce symptoms, such as scaling, shedding, flaking, itching, pain and burning.1

What you need to know before you use your medication1

Please consult the Patient Information Leaflet (PIL) prior to use and always follow the guidance of your healthcare professional when administering this medication.

Prefilled pen
  • If you are allergic to guselkumab or any of the other ingredients of this medicine. The other ingredients contained in your treatment are histidine, histidine monohydrochloride monohydrate, polysorbate 80, sucrose and water for injections. If you think you may be allergic, ask your doctor for advice before starting your treatment
  • If you have an active infection, including active tuberculosis
Warning

Talk to your doctor, pharmacist or nurse before using this medication if:

  • You are being treated for an infection
  • You have an infection that does not go away or that keeps coming back
  • You have tuberculosis or have been in close contact with someone with tuberculosis
  • You think you have an infection or have symptoms of an infection (see below under ‘look out for infections and allergic reactions’)
  • You have recently had a vaccination or if you are due to have a vaccination during treatment

If you are not sure if any of the above applies to you, talk to your doctor, pharmacist or nurse before using this medicine.

As directed by your doctor, you may need blood tests to check if you have high levels of liver enzymes before you start taking Tremfya® and when using it. Increases in liver enzymes may occur more frequently in patients receiving Tremfya® every 4 weeks than in patients receiving Tremfya® every 8 weeks.

Allergy

This medication may lower your ability to fight infections and may therefore increase your risk of infections and allergic reactions. Tell your doctor or seek medical help immediately if you notice any signs of an infection or an allergic reaction while you are using your medication.

Some of the symptoms of infection can be:

  • Fever or flu-like symptoms
  • Muscle aches
  • Cough
  • Shortness of breath
  • Burning sensation when you urinate, or urinating more often than usual
  • Blood in your phlegm (mucus)
  • Weight loss
  • Diarrhoea or stomach pain
  • Warm, red or painful skin or sores on your body which are different from your psoriasis

Some of the symptoms and signs of an allergic reaction can be:

  • Swelling of the face, lips, mouth, tongue or throat
  • Difficulty swallowing or breathing
  • Severe itching of the skin, with a red rash or raised bumps (hives)3
Medication

Tell your doctor or pharmacist:

  • If you are using, have recently used or might use any other medicines
  • If you recently had or are due to have a vaccination. You should not be given certain types of vaccines (live vaccines) while using this treatment. Speak with your healthcare professional prior to having any vaccinations
Pregnancy
  • This treatment should not be used in pregnancy as the effects of this medicine in pregnant women are not known. If you are a woman of childbearing potential, you are advised to avoid becoming pregnant and must use adequate contraception while using your medication and for at least 12 weeks after the last dose. Talk to your doctor if you are pregnant, think you may be pregnant or are planning to have a baby
  • Talk to your doctor if you are breast-feeding or are planning to breast-feed. You and your doctor should decide if you will breast-feed or use this treatment
Driving
  • Your medication is unlikely to influence your ability to drive and use machines.
Administer

Please see the Patient Information Leaflet for instructions on how to administer your medication

Reporting side effects

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at: https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. You can also call Janssen-Cilag Ltd Drug Safety on 01494 567447 or at dsafety@its.jnj.com.

By reporting side effects you can help provide more information on the safety of this medicine.

References

  1. Tremfya® Patient Information Leaflet. Available from: https://www.medicines.org.uk/emc/files/pil.9587.pdf [Last accessed March 2021].
  2. The National Psoriasis Foundation. Biologics. Available from: https://www.psoriasis.org/about-psoriasis/treatments/biologics [Last accessed March 2021].
  3. National Health Service: Hives. Available from: https://www.nhs.uk/conditions/hives [Last accessed March 2021].

How to administer your medication

Please see the video for how to administer the pre-filled pen.

If you and your healthcare professional decide that self-injecting your medication is a suitable option, you will receive appropriate training on how to do so. It is important not to try to inject yourself until you have been trained by your doctor or nurse.1

Reporting side effects

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at: https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. You can also call Janssen-Cilag Ltd Drug Safety on 01494 567447 or at dsafety@its.jnj.com.

By reporting side effects you can help provide more information on the safety of this medicine.

References

  1. Tremfya® Patient Information Leaflet. Available from: https://www.medicines.org.uk/emc/files/pil.9587.pdf [Last accessed March 2021].

How often to use your medication

Your medication is supplied as an injectable pre-filled pen for administration by a subcutaneous injection, meaning an injection under the skin.1

Your treatment dose is 100 mg, which is the content of one pre-filled pen.1

At the beginning of your treatment, you will receive one dose at weeks 0 and 4, followed by one dose every 8 weeks thereafter.1

An example dosing schedule for a patient receiving their first dose on 1st January.1

Doising Chart Infographic

Always use this medication exactly as your doctor or nurse has advised you. If you are unsure or have any questions about your dose, speak to your doctor or nurse.1

Your treatment journey: what to expect

Your healthcare professional has prescribed Tremfya® for your psoriasis. If you are starting on this medication, you may be wondering how often you will receive it and what might happen during the course of your treatment. The timeline below provides you with this information.

WEEK 4: THE SECOND DOSE

You're on your way, you have taken the first two doses!

WEEK 20: THE FOURTH DOSE

From this point onwards, you will keep receiving a dose every 8 weeks. Your doctor will decide for how long you need to use this medication.1

Make sure you continue your treatment as prescribed and that you’re staying in touch with your doctor or nurse in case you have any questions. You may wish to also keep tracking your progress yourself to see how far you’ve come.

Reporting side effects

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at: https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. You can also call Janssen-Cilag Ltd Drug Safety on 01494 567447 or at dsafety@its.jnj.com.

By reporting side effects you can help provide more information on the safety of this medicine.

References

  1. Tremfya® Patient Information Leaflet. Available from: https://www.medicines.org.uk/emc/files/pil.9587.pdf [Last accessed March 2021].
  2. Janssen-Cilag Ltd. Tremfya® (guselkumab) Summary of Product Characteristics. Available from: https://www.medicines.org.uk/emc. [Last accessed March 2021].

Possible side effects1

Reporting side effects

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at: https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. You can also call Janssen-Cilag Ltd Drug Safety on 01494 567447 or at dsafety@its.jnj.com.

By reporting side effects you can help provide more information on the safety of this medicine.

What are the possible side effects?

Like all medications, Tremfya® may cause side effects.

Please refer to the Patient Information Leaflet (PIL) for more information and always consult your doctor should you have any concerns.

Very common side effects:1

(may affect more than 1 in 10 people)

  • Respiratory tract infections

Common side effects1

(may affect up to 1 in 10 people)

  • Headaches
  • Joint pain (arthralgia)
  • Diarrhoea
  • Redness, irritation or pain at the injection site
  • Increased level of liver enzymes in the blood*

*As directed by your doctor, you may need blood tests to check if you have high levels of liver enzymes before you start taking Tremfya® and when using it. Increases in liver enzymes may occur more frequently in patients receiving Tremfya® every 4 weeks than in patients receiving Tremfya® every 8 weeks.1
This was discovered in the clinical trials for Tremfya® in psoriatic arthritis.2 Tremfya® is only given every 4 weeks for some patients with psoriatic arthritis.1

Uncommon side effects:1

(may affect up to 1 in 100 people)

  • Allergic reaction
  • Skin rash
  • Decreased number of a type of white blood cell called neutrophils
  • Herpes simplex infections
  • Fungal infection of the skin, for instance between the toes (e.g., athlete's foot)
  • Stomach flu (gastroenteritis)
  • Hives

Possible serious allergic reaction1

(may affect up to 1 in 100 people) - the signs may include:

  • Difficulty breathing or swallowing
  • Swelling of the face, lips, tongue or throat
  • Severe itching of the skin, with a red rash or raised bumps

Reference

  1. Tremfya® Patient Information Leaflet. Available from: https://www.medicines.org.uk/emc/files/pil.9587.pdf [Last accessed March 2021].
  2. Janssen-Cilag Ltd. Tremfya® (guselkumab) Summary of Product Characteristics. Available from: https://www.medicines.org.uk/emc [Last accessed March 2021].